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with pharmacist-managed ESA clinics (n314) and at six sites with usual care only
(n167); outpatients were followed for 6months in 2009.We took a VA perspective
with projections over a five-year time horizon; costs and effectiveness values were
discounted at 3%/yr. Strategy-specific likelihoods of target range hemoglobin val-
ues (10-12 g/dl) were based on study results. Utilities for ND-CKD and ESA-related
adverse events and their likelihood were obtained from the literature. ESA costs
were based on average monthly epoetin and darbepoetin doses per patient during
the study and VA ESA cost data. RESULTS: In the base case analysis, cost and effec-
tivenesswere$12,500and2.096quality-adjusted life-years (QALYs) in thepharmacist-
managed ESA clinics and $15,500 and 2.093 QALYs in usual care; ESA clinics domi-
nated usual care. In one-way sensitivity analyses, ESA clinics no longer dominated if
theirpatients’probabilityofbeing in the target range fell to0.54 (basecase0.71)or if the
mean cost/month of epoetin or darbepoetin in ESA clinics increased to approximately
$360 (base case $211) or $460 (base case $250), respectively.When all parameterswere
varied simultaneously in a probabilistic sensitivity analysis, ESA clinics were favored
80% of the time regardless of willingness-to-pay threshold. CONCLUSIONS: Phar-
macist-managed ESA clinics were less costly and more effective than usual care in
patients receiving ESAs for anemia andND-CKD. Results were robust to variation and
support the use of pharmacist-managed ESA clinics.
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OBJECTIVES: Immunosuppressive agents have affected the incidence of acute re-
jection and early graft survival. The purpose of this study was to evaluate the
cost-utility of sirolimus versus tacrolimus for primary prevention of graft rejection
in renal transplant recipients using the Mexican Institute of Social Security (IMSS)
perspective. METHODS: A Markov model was developed to estimate the cost-ef-
fectiveness of sirolimus versus tacrolimus to prevent graft rejection in adult pa-
tients with end-stage renal disease (ESRD). The model estimates total costs and
QALYs per patient in each prophylaxis group. To extrapolate trial results to lifetime
horizon, the model was extended through one-year Markov cycles. The probabili-
ties of experiencing a graft loss, dialysis, and death were estimated from trial
published data; long-term mortality, acquisition costs, and direct treatment costs
were retrieved using IMSS published sources. Cost utility assessment was ex-
pressed in terms of cost per QALY gained. All costs are presented in 2011US dollars.
Probabilistic sensitivity analyses were carried out to test the robustness of the
results. RESULTS: In comparison to tracolimus, sirolimus improved life expec-
tancy, number of QALYs gained, and reduced incidence of complications. The life-
time overall costs of prevent graft rejection in adult patients with ESRD resulted in
a cost per QALY gained of $5846. Over the lifetime period, sirolimus was esti-
mated to gain 8.18 QALYs per patient compared to 7.33 QALYs for tacrolimus.
Sirolimus is estimated to be cost-saving compared to tacrolimus. Notably, results
suggest that sirolimus has a 78% probability of being dominant over tacrolimus
strategy, with 100% of probability in showing an incremental cost-effectiveness
ratio at or below US$13,000 (1 GDP per capita in Mexico) per QALY gained.
CONCLUSIONS: This analysis suggests that at IMSS, sirolimus in comparison to
tacrolimus for prevention of graft rejection in adults patient with ESRD is likely to
be cost saving alternative.
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OBJECTIVES: To carry out a cost-utility analysis comparing initial treatment of
patients with overactive bladder (OAB) with solifenacin 5 mg/day versus either
trospium 20mg twice a day or trospium 60 mg/day from the perspective of the
German National Health Service. METHODS: A decision analytic model with a
three-month cycle was developed to follow a cohort of OAB patients treated with
either solifenacin or trospium during a one-year period. Costs and utilities were
accumulated as patients transitioned through the four cycles in themodel. Some of
the solifenacin patients were titrated from 5mg to 10mg/day at 3 months. Utility
values were obtained from the published literature and pad use was based on a US
resource utilisation study. Adherence rates for individual treatments were derived
from a UK GP database review. The change in themean number of urgency urinary
incontinence episodes/day from after 12 weeks was the main outcome measure.
Baseline effectiveness values for solifenacin and trospium were calculated using
the Poisson distribution. Patients who failed second-line therapy were referred for
a specialist visit. Results were expressed in terms of incremental cost-utility ratios.
RESULTS: Total annual costs for solifenacin, trospium 20mg and trospium 60mg
were 982.28 €, 863.23 € and 880.37 € respectively. Drug use represented 47%, 32%and
33% of total costs and pad use varied between 42% and 55%. Differences between
cumulative utilities were small but favoured solifenacin (0.6887 vs. 0.6828 to
0.6830). The baseline incremental cost-effectiveness ratio ranged from 17,104 € to
20,533 per QALY. CONCLUSIONS: Solifenacin would appear to be cost-effective
with an incremental cost-utility of no more than 21,000 €/QALY. Small differences
in utility between the alternatives, however,means that the results are sensitive to
adjustments in the values of the assigned utilities, effectiveness and discontinua-
tion rates.
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OBJECTIVES: To compare the utility scores and quality of life scores between pa-
tients who have twice and thrice-weekly hemodialysis. METHODS: This was a
cross-sectional analytical study in 5 hemodialysis sites ofNephrologyUnit at Siriraj
Hospital (the largest university hospital in Thailand), Face-to-face interview using
EuroQol questionnaire (EQ-5D), VAS, and KDQOL-36 (consists of 3 kidney disease
subscales and SF-12) was conducted between April 2011 and June 2011, one hun-
dred and fifty-three hemodialysis patients were recruited from the chronic hemo-
dialysis clinic unit. This study compared the difference of hemodialysis times in
weekly to utility scores and quality of life scores of patients by using Independent
Student’s t-test. RESULTS: SF-6D (derived from SF12), EQ-5D (UK and Thai prefer-
ence weight), and VAS between the patients who received twice and thrice-weekly
hemodialysis were not significantly different (p0.05). This is true as well for
Symptom/ problem list, Effects of kidney disease, and burden of Kidney Disease
scores. For SF-12, all of physical and mental domains were not significantly differ-
ent as well as all of utility and kidney disease specific scores were not significantly
associated with hemodialysis times in weekly intervals (all, p0.05).
CONCLUSIONS: These findings implied that thrice-weekly could not reflect the
better quality of life than twice-weekly hemodialysis. There was no significant
difference quality of life from the Symptom/ problem list, Effects of kidney disease,
and burden of Kidney Disease between twice and thrice-weekly hemodialysis as
well as the utility scores from SF-6D, EQ-5D and VAS. Further large cohort study of
utility scores or cost effectiveness analysis between the difference of dialysis fre-
quency at weekly intervals, however, should be conducted.
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OBJECTIVES: Analysis of EQ-5D data often focuses on changes in utility, ignoring
valuable information from other parts of the instrument. Our objective was to
explore how the utility index, EQ-5D profile, and EQ-VAS captured change in clin-
ical trials of Mirabegron, a new treatment for overactive bladder (OAB).METHODS:
Data were pooled from three phase III clinical trials that investigated the efficacy
and safety of mirabegron versus placebo. Tolterodine ER 4mg was included as an
active control in one study: 1) Europe and Australia (placebo,mirabegron 50mg and
100mg, and tolterodine 4mg ER); 2) USA andCanada (Placebo,Mirabegron 50mg and
100mg); and 3) USA, Canada and Europe (Placebo, and Mirabegron 25mg and 50mg.
Data were collected at baseline, week 4, 8 and 12. Analyses were performed on full
analysis and per protocol data sets using UK utilities. Analysis controlled for rele-
vant patient characteristics. Analysis of Covariance identified changes from base-
line at each time point in utilities and EQ-VAS, while Areas Under the Curve (AUC)
were estimated to summarise intertemporal differences in effect. RESULTS: In per
protocol analyses, mirabegron 50mg was superior to tolterodine 4mg in changes
from baseline utilities after 12 weeks (p0.05); similarly, AUC results showed mi-
rabegron 50mg to be superior to tolterodine (p0.05) and to placebo (p0.05). In
both cases, the benefit is already apparent at 4 weeks (p0.05). EQ-VAS more con-
sistently indicated superior outcomes: all three mirabegron doses showed statisti-
cally significant greater effectiveness compared to tolterodine at 12 weeks. Indi-
vidual EQ-5D dimensions and the overall profile showed no significant differences
between study arms. CONCLUSIONS: Despite slight contrasts in results between
the EQ-5D derived utilities and EQ-VAS, mirabegron showed quicker and superior
improvement in HR-QoL compared to tolterodine 4mg ER. Research is required to
address future utilitymeasurements, especially in relation to EQ-5D dimensions in
OAB patients.
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OBJECTIVES: Examine role of caregiver in supporting treatment decisions towards
blood transfusions among individuals with chronic kidney disease (CKD) currently
not on dialysis.METHODS: An online survey was conducted in 1Q2011. All respon-
dents were18 years and diagnosed with Cancer by a physician. Participants were
asked about blood transfusion history, presence of anemia, types and roles of
caregivers in assisting with management of their CKD and making health and
treatment decisions towards blood transfusion. RESULTS: Of 416 participants, 59%
(n246)were female; 40% (n165)were65 years. 35% (n144) had stage 4 and 58%
(n240) stage 3 CKD. 54% (n226) were anemic. 43% (n179) had received blood
transfusion, whereas, 57% (n237) had no transfusions. 53% (n220) reported that
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no one helped with their daily activities, 36% (n150) said their spouse helped
them, followed by child (9%, n37), friend (7%, n29), another relative (5%, n21),
parent (3%, n12), paid helper (3%, n12), visiting doctor/nurse (3%, n12). Among
those who sought caregiver help on daily basis (n195), two-thirds (64%) reported
being cared for by spouse, 42% said a friend, and 21% their child. When asked, who
helped (always/sometimes) in making health and medical care decision, 86% said
spouse, 51 % friend, and 46% child. Almost two-thirds (63%) indicated they had
right amount of caregiver support in making treatment choice for blood transfu-
sion, 61% reported they made an informed decision, whereas, 40% said they felt
pressured by others. Higher percentage (74%) of previously transfused individuals
agreed they have right amount of caregiver support inmaking a transfusion choice
compared to not transfused group (55%). CONCLUSIONS: Caregivers play an im-
portant role in helping individuals with their health and medical treatment deci-
sions. On a daily basis, primary caregivers are spouse, child, and friend. Individuals
have right amount of caregiver support when making treatment decisions.
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OBJECTIVES: Post-transplant expectations can be overwhelming. We assessed the
relationship between health literacy and unmet immunosuppressant (IS) drug in-
formation needs in kidney transplant recipients. We hypothesized that patients
with low health literacy have greater unmet IS drug information needs compared
to patients with optimal health literacy. METHODS: A cross-sectional survey was
mailed out to 300 kidney transplant patients recruited from a single urban trans-
plant center. Inclusion criteria were receiving post-transplant care at the center
and receiving the transplant 1 to 36 months before inception of the survey. A
validated scale measured functional, communicative and critical health literacy.
An unmet IS drug information need was defined as a person reporting some to a
significant problem and too little information on areas related to IS drug manage-
ment. A personwith 7 ormore unmet IS drug information needswas categorized as
having high unmet IS drug information needs. Logistic regression was used to
produce unadjusted and adjusted OR controlling for age, race, gender, and time
since transplant. RESULTS: A response rate of 50% was obtained. 61.3% of respon-
dents weremale and themean agewas 56.7 (/ 11.2) years. Cronbach’s alphas for
functional, communicative, and critical health literacy respectively were 0.87, 0.88
and 0.83. Patients with high functional health literacy (ORunadjusted: 0.23 [0.07,
0.82]; ORadjusted: 0.26 [0.06, 1.09]) and patients using the transplant staff as a
source of information about transplant medications (ORunadjusted: 0.43 [0.19,
0.94]; ORadjusted: 0.28 [0.10, 0.78]) were less likely to report high unmet IS drug
information needs. CONCLUSIONS: Patients with low functional health literacy
have high unmet IS drug information needs, which might affect the management
of their condition. It is important to assess patients’ health literacy, tailor commu-
nication and materials accordingly, and regularly reinforce IS issues in order to
meet their IS drug information needs.
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OBJECTIVES: Examine knowledge and information seeking behaviors towards
blood transfusions among individualswithChronic KidneyDisease (CKD) currently
not on dialysis. METHODS: An online survey was conducted from a nationally
representative patient panel in 1Q2011. Respondents were 18 years and diag-
nosed with CKD by a physician. Participants were asked about blood transfusion
history, information seeking behaviors, and knowledge about blood transfusion.
RESULTS: Of 416 respondents, 59% (n246) were female; 40% (n165) were 65
years. 35% (n144) had stage 4 and 58% (n240) stage 3 CKD. 54% (n226) were
anemic. 43% (n179) had received blood transfusion, whereas, 57% (n237) had no
transfusions. Top two sources of information were doctor (93.8%) and Internet
(80.5%). Among those previously transfused, 62% received right amount of infor-
mation, whereas, 34.6% received too little information, and 3.4% reported receiving
too much information. More than 80% of transfused indicated they knew the rea-
sons for and benefits of getting a blood transfusion. Less than two-thirds received
information about effects, risks, and time it would take, and only 26% knew the
costs. Over 60% said that it is extremely important to know right blood type, screen-
ing techniques and quality of blood, and risks of infections. Among previously
transfused, only half (50%) agreed that theymade an informed choice about receiv-
ing blood transfusions. Among the previously transfused, 77% agree that they
knew the benefits compared with 49% not transfused. Similarly among previously
transfused, 69% agreed that they knew the risks of blood transfusion compared to
51% with no transfusion history. CONCLUSIONS: Doctor’s office and Internet are
primary sources of information about blood transfusions. Gaps in knowledge exist
about benefits, risks, and costs of blood transfusions. A significant number feel that
they need more information about blood transfusion to make an informed choice.
Providers should consider adopting shared-decision making with their patients.
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OBJECTIVES: To evaluate the reliability and validity of the Thai translation of the
KDQOL-36 questionnaire, by focus on kidney disease specific dimensions. The
KDQOL-36 consists of SF-12, and 3 dimensions of kidney disease questionnaires
(the Symptom/ Problem list, Effects of Kidney Disease on Daily Life, and Burden of
Kidney disease).METHODS: Subjects were 167 hemodialysis patients and 62 peri-
toneal dialysis patients. Reliability was evaluated by using intraclass correlation
coefficients (ICCs) for test-retest reliability assessment with face to face inter-
view and Cronbach’s alpha for internal consistency. Construct validity was sup-
ported with convergent and discriminant validity using correlation between
SF-36, EQ-5D, VAS parameter and 3 dimensions of kidney disease question-
naires. Statistical analysis included descriptive statistics, Mann-Whitney U test,
and Cronbach’s alpha. RESULTS: Construct validity was satisfactory with the sig-
nificant difference less than 0.001 between two groups (lowest through 25 percen-
tile and higher than 75 percentile). The reliability coefficient for the Cronbach’s
alpha of the total scale of the KDQOL-36 were greater than 0.700 for all domains,
range from 0.706 to 0.827. ICCs ranging from 0.713 to 0.999. CONCLUSIONS: The
KDQOL-36 (Thai) is an appropriate tool for quality of life assessment and routine
care in dialysis patients.
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OBJECTIVES: Initial mass dose, renal disease recurrence, and immunosuppressant
nephrotoxicity affect long term graft function after kidney transplantation (KTx).
Chronic Kidney Disease (CKD) may impair work ability, job performance and in-
crease absenteeism. We sougt to evaluate the association of post-transplant CKD
with work ability and labor supply.METHODS:We contacted all patients at 2 Mid-
western KTx clinics. All consenting patients answered a questionnaire about socio-
demographic characters, working conditions, quality of life and work ability (Work
Ability Index, WAI). A second survey about labor supply was sent after 6 months.
We abstracted biochemistry results, treatments and comorbidities data from clin-
ical charts. We excluded patients with multiple or multi-organ transplant, and
laboratory evidence of an acute cardiac ischemic episode in the month prior to
assessment. At least one creatinine assessment in the 3 months screening period
and age between 18-65 yearswas required for inclusion.We assessed differences in
WAI and labor supply across CKD stages and Glomerular Filtration Rate (GFR) with
ordinary least square regression. RESULTS: We enrolled 577 patients in 2 mid-
westen clinic (response rate 82%). Of them 222met the inclusion/exclusion criteria.
The employment-to-population ratio was 63%. MeanWAI score was 38.85.9. CKD
severity was associated with WAI ( -0.24, p0.01). GFR was associated with WAI
after adjusting for possible confounders (0.06; p0.01). Ninty-three percent of
patients responded to the follow up survey. Of those employed at baseline 20% lost
their job and 25% of previously jobless had found one. Patients with severe CKD
worked 4.69 weeks less than subject with mild or moderate CKD (p0.03). GFR was
associated with labor supply during the 6-months follow up after adjusting for
possible confounders (0.07; p0.03) CONCLUSIONS: Severe CKD was associated
with a mild reduction in self-reported work ability and a strong reduction in labor
supply after kidney transplant.
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OBJECTIVES: Hemodialysis (HD) patients are frequently hospitalized. Interruption
of normal dialysis and 3x/weekly ESA treatments, along with the cause of hospi-
talization, usually leads to declines in Hb and increased ESA utilization post-hos-
pitalization. To determine the impact of these changes on patient care and re-
source utilization, we assessed the time for HD patients to recover to pre-
hospitalization ESA dose levels. METHODS: In this retrospective time-to-event
analysis, we examined hospitalizations in adult (318 yrs old) HD patients from
January 1, 2009 to December 31, 2010. Hospitalizations preceded by  30 hospital-
free days were included. For patients experiencing increases in epoetin alfa (EPO)
dose in the 30 days after hospitalization versus the 30 days before, we determined
the number of days taken to achieve an EPO dose  the median per-session dose
before hospitalization. Patient timewas censored at re-hospitalization, transplant,
death, or discontinuation of dialysis. Pre-hospitalization EPO dose level was con-
sidered achieved at the first of 3 consecutive dialysis sessionswhere EPOwas given
at a dose  the median per-session dose in the 30 days pre-hospitalization.
RESULTS: A total of 88,627 hospitalization events were analyzed where EPO use
increased post-hospitalization; in 40% of these cases patients were censored
(mainly due to re-hospitalization) before reaching pre-hospitalization dose. Of
those where EPO dose recovered to pre-hospitalization levels, median time to
recovery was 49 days (mean 102 days). Restricting the analysis to patients with
pre-hospitalizationmedian doses not in the top or bottom 10% of the range gave
a median time to recovery of 51 days (mean 90 days). CONCLUSIONS: Hospital-
izations frequently require an increase in post-hospitalization EPO dose. In
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